UROGEN PHARMA LTD (URGN) competitors & alternatives
Health Care · NASDAQ
UROGEN PHARMA LTD (URGN)'s top competitors and alternatives — its most similar public companies — include Bristol Myers Squibb (BMY), Merck & Co. (MRK), RELMADA THERAPEUTICS INC (RLMD), WHITEHAWK THERAPEUTICS INC (WHWK), OCULAR THERAPEUTIX INC (OCUL), XERIS BIOPHARMA HOLDINGS INC (XERS), AMNEAL PHARMACEUTICALS INC CLASS A (AMRX), CG ONCOLOGY INC (CGON), PROTARA THERAPEUTICS INC (TARA), IMMUNITYBIO INC (IBRX), AURA BIOSCIENCES INC (AURA) and Genelux Corp (GNLX). These are UROGEN PHARMA LTD's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top URGN competitors & alternatives
-
Bristol Myers SquibbBMYHealth Care
Bristol Myers Squibb is a leading biopharmaceutical company specializing in advanced oncology, immunology, and cardiovascular therapies using diverse…
$60.76 (as of 2026-07-22) · market cap $124.9B
-
Merck & Co.MRKHealth Care
Global pharmaceutical and vaccine leader with oncology, infectious disease, and animal health franchises, anchored by blockbuster immunotherapy Keytruda.
$127.47 (as of 2026-07-22) · market cap $315.3B
-
RELMADA THERAPEUTICS INCRLMDHealth Care
Clinical-stage biotech redirecting toward oncology and neurology with in-licensed chemotherapy delivery and neurosteroid platforms after terminating its lead…
$5.00 (as of 2026-07-22) · market cap $524M
-
WHITEHAWK THERAPEUTICS INCWHWKHealth Care
Clinical-stage oncology company developing next-generation antibody-drug conjugates (ADCs) targeting validated tumor antigens with advanced linker-payload…
$3.99 (as of 2026-07-22) · market cap $216M
-
OCULAR THERAPEUTIX INCOCULHealth Care
Ocular Therapeutix is a biopharmaceutical company leveraging proprietary bioresorbable hydrogel technology to deliver retinal therapies, with AXPAXLI…
$8.59 (as of 2026-07-22) · market cap $2.0B
-
XERIS BIOPHARMA HOLDINGS INCXERSHealth Care
A commercial-stage biopharma company with three FDA-approved therapies for rare endocrine and neurological diseases and a proprietary injectable drug…
$8.38 (as of 2026-07-22) · market cap $1.5B
-
AMNEAL PHARMACEUTICALS INC CLASS AAMRXHealth Care
Amneal Pharmaceuticals is a diversified biopharma company providing a broad range of essential, affordable generic and specialty medicines, alongside…
$17.75 (as of 2026-07-22) · market cap $5.7B
-
CG ONCOLOGY INCCGONHealth Care
An early-stage immuno-oncology company developing cretostimogene, a novel therapeutic candidate for high-risk and intermediate-risk non-muscle-invasive bladder…
$69.31 (as of 2026-07-22) · market cap $6.3B
-
PROTARA THERAPEUTICS INCTARAHealth Care
Clinical-stage biopharmaceutical company developing TARA-002, a cell therapy based on an established immunopotentiator, and IV Choline Chloride for oncology,…
$4.08 (as of 2026-07-22) · market cap $229M
-
IMMUNITYBIO INCIBRXHealth Care
ImmunityBio develops engineered natural killer cell and cancer vaccine therapies, led by its approved ANKTIVA treatment for bladder and lung cancers, to…
$7.51 (as of 2026-07-22) · market cap $8.0B
-
AURA BIOSCIENCES INCAURAHealth Care
Aura Biosciences is a clinical-stage biotech developing precision Viral-like Drug Conjugate (VDC) therapies designed to treat solid tumors while preserving…
$7.01 (as of 2026-07-22) · market cap $725M
-
Genelux CorpGNLXHealth Care
Genelux is a late clinical-stage biopharmaceutical company developing oncolytic vaccinia virus immunotherapies designed to selectively kill tumor cells and…
$2.96 (as of 2026-07-22) · market cap $131M
Not quite? Describe exactly what you want →
Peers are UROGEN PHARMA LTD's closest public companies by shared sub-industry, sector and business themes. See the full profile: UROGEN PHARMA LTD (URGN).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.